Results 221 to 230 of about 37,095 (249)
Some of the next articles are maybe not open access.
European Journal of Cancer, 1993
Ondansetron is the first selective antagonist of the 5-hydroxytryptamine receptors (type 3) marketed for the prevention of emesis induced by antineoplastic agents. Ondansetron has been shown to be more active and less toxic than high-dose metoclopramide in patients submitted to cisplatin chemotherapy.
F, Roila +8 more
openaire +3 more sources
Ondansetron is the first selective antagonist of the 5-hydroxytryptamine receptors (type 3) marketed for the prevention of emesis induced by antineoplastic agents. Ondansetron has been shown to be more active and less toxic than high-dose metoclopramide in patients submitted to cisplatin chemotherapy.
F, Roila +8 more
openaire +3 more sources